Targets › PBPN
2 programs from 2 companies in 2 trials: 2 Phase 4; Infectious disease, Respiratory; next expected readout Jun 2028.
Open in Phaseline: the race on PBPN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Scandinavian Critical Care Trials Group | Tazobactam Bacterial beta-lactamase TEM inhibitor | PBPN | Phase 4 | Sepsis | Jun 2028 |
| Tejs Ehlers Klug | Penicillin G Bacterial penicillin-binding protein inhibitor | PBPN | Phase 4 | Acute Tonsillitis | Dec 2028 |
Sepsis (1) Acute Tonsillitis (1)
small molecule (2)
Scandinavian Critical Care Trials Group (1) Tejs Ehlers Klug (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.